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Abstract 
Patients with advanced germ cell tumors can be cured with cisplatin-based 
chemotherapy, but the outcome remains unsatisfactory for patients with relapsed 
disease, including those patients with refractory disease after bone marrow 
transplantation. Targeted therapies have changed the standard of care for many 
advanced solid tumors. We have identified, in the literature, potential targets for the 
treatment of refractory germ cell tumors, and applied to a patient with a refractory 
disease. We chose sunitinib for this purpose. To our knowledge, this is the first case to be 
treated with sunitinib, and we have found a promising activity. 
 
Introduction 
Cancer of the testis comprises a morphologically and clinically diverse group of 
neoplasms, most of which are germ cell tumors (GCT). Approximately 90% of the GCT 
originate in the testis and 10% are extragonadal. 
20 to 30% of patients with advanced GCT relapse or fail to achieve a complete response 
to conventional cisplatin-based chemotherapy. Effective second- and third-line salvage 
options offer a possibility of cure for those patients whose disease displays a resistance to 
bleomycin, etoposide and cisplatin (BEP) as first-line therapy. 
The chemosensitivity of GCT, a striking dose-response phenomenon for individual 
drugs, the rare occurrence of bone marrow metastasis, and a young patient population 
permit administration of high-dose chemotherapy (HDT) with refractory GCT. Options 
for patients who recur after bone marrow transplantation are few and patients usually 
have a bad prognosis.  
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Sunitinib (SU011248; SUTENT, Pfizer Inc., New York, N.Y., USA) is a rationally 
designed small molecule that inhibits members of the split-kinase domain family of 
receptor tyrosine kinases (RTKs), including the vascular endothelial growth factor 
receptors (VEGFRs) types 1 and 2 (FLT1 and FLK1/KDR), platelet-derived growth factor 
receptors (PDGFR-α and PDGFR-β), stem cell factor receptor c-KIT, and FLT3 and RET 
kinases [1–3]. Inhibition of these RTKs blocks signal transduction, thereby affecting many 
of the processes involved in tumor growth, progression, metastasis, and angiogenesis [4]. 
The VEGF, basic fibroblast growth factor (bFGF), and PDGF-signaling pathways are 
critical in the transduction of extracellular signals and the induction of angiogenesis [1]. 
Angiogenesis plays a vital role in the growth and metastasis of solid and hematologic 
malignancies [5]. Receptors such as c-KIT, FLT3, and RET are also important in signal 
transduction and growth in solid tumors, including gastrointestinal stromal tumors 
(GIST), small-cell lung cancer, thyroid carcinoma, and hematologic malignancies such as 
lymphomas and leukemias [1, 6, 7]. 
RTK Inhibition by Sunitinib 
RTKs are transmembrane proteins at the cell surface that transduce extracellular 
signals to the cytoplasm [1, 2]. These proteins contain extracellular ligand-binding 
domains and intracellular catalytic domains. Ligand binding induces dimerization of 
these RTKs resulting in autophosphorylation of the cytoplasmic domains and activation 
of tyrosine kinase activity. Tyrosine kinase activation further stimulates multiple 
downstream signaling pathways that modulate DNA synthesis, cell division, growth, 
progression, migration, differentiation, and cell death [1, 2]. The predominant RTKs that 
have been demonstrated to be inhibited by sunitinib are VEGF, PDGF, bFGF, KIT, FLT3, 
CSF-1, and RET [3, 8] 
VEGF, PDGF, and bFGF RTK Inhibition 
VEGF is a robust growth factor for endothelial cell proliferation and angiogenesis that 
promotes the vascularization required for primary tumor growth and for establishing new 
metastatic foci [5, 9]. An abundance of data exists that associates excessive levels of VEGF 
expression with increased microvascular density, cancer recurrence, and decreased 
survival. The VEGF receptors, VEGFR1 (also known as Flt-1), VEGFR2 (also known as 
Flk1 or KDR), and VEGFR3 (also known as Flt4), possess tyrosine kinase activity that 
promotes intracellular signaling, leading to downstream effects on angiogenesis [10]. 
PDGF has two receptor types, α and β, which are both overexpressed in many solid 
tumors as well as in the surrounding stroma [1, 11]. PDGFR is upregulated during tumor 
progression to stimulate the growth and proliferation of pericytes and fibroblasts that 
surround and support endothelial cells [12]. bFGF and its receptor are expressed in a 
variety of tumors and are involved in promoting tumor growth directly, or indirectly, 
through stimulation of angiogenesis and induction of VEGF expression [10]. 
Doses of 20 to 40 mg/kg/day were needed to achieve the target plasma concentrations 
(50 to 100 ng/ml) required to demonstrate inhibition of VEGFR2 and PDGFR 
phosphorylation [3].  
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Other RTKs Inhibited by Sunitinib 
FLT3 RTK Inhibition. FLT3 (fms-related tyrosine kinase, Flk2, stk-2) is expressed on 
immature hematopoietic progenitors as well as some mature myeloid and lymphoid cells 
[7, 13]. This RTK regulates the survival and proliferation of hematopoietic progenitor 
cells, whereas mutations of FLT3 in acute myelogenous leukemia (AML) are associated 
with enhanced proliferation and survival of leukemic blasts [7].  
KIT, CSF-1R, and RET RTK Inhibition. c-KIT is produced by the KIT gene, which is 
expressed on hematopoietic progenitor cells, mast cells, germ cells, and the interstitial cell 
of Cajal [6, 14]. Steel factor (SLF or stem cell factor) is the ligand that binds to c-KIT and 
initiates signal transduction. c-KIT has been implicated in mastocytosis/mast cell 
leukemia, germ cell cancers, small-cell lung cancer, GISTs, AML, neuroblastoma, 
melanoma, and ovarian and breast carcinoma [6, 15]. Despite these in vitro cellular 
potencies, sunitinib doses of 40 to 80 mg/kg/day were still required to produce adequate 
plasma levels for inhibition of the c-KIT RTK. 
Colony-stimulating factor (CSF)-1R is a c-fms gene product that exists on monocytic 
progenitors [16, 17]. The osteoclastogenic factor, macrophage CSF produced by tumor 
cells, binds to the CSF-1R receptors to stimulate osteoclasts and enhance the osteolytic 
activity of osteoclasts. A mutant form of the RET proto-oncogene RTK is involved in the 
multiple endocrine neoplasia types 2A and 2B autosomal dominant syndromes, familial 
medullary thyroid carcinoma, and perhaps sporadic neuroendocrine tumors [2, 18]. In 
cultured TT human medullary thyroid carcinoma cells with an active RET mutation, 
sunitinib inhibited RET autophosphorylation with an IC50 of approximately 100 nmol/l, 
indicating that these tumors may be an appropriate target for disease-directed studies 
[19]. 
Rationale for the Use of Sunitinib in GCT 
RTKs play a major role during all developmental stages of the male gonad. The RTK 
c-KIT is a key regulator of spermatogenesis that was detected in early gonadal 
development [20]. Its ligand, stem cell factor (SCF), is produced by the Sertoli cells of the 
testis [21]. c-KIT is expressed in 80–100% of seminomas but in only 7–32% of non-
seminoma tumors [22]. Activating c-KIT mutations are rare in GCTs [23]. c-KIT 
mutations in exon 17 were detected in 3/224 unilateral and 57/61 bilateral GCTs [24]. 
Physiological and neoplastic angiogenesis are mediated by vascular endothelial growth 
factor (VEGF) and its action on the receptor vascular endothelial growth factor receptors 
(VEGFR) and other growth factors. VEGF binds to the RTKs VEGFR1 and VEGFR2, 
which are expressed on endothelial cells. While VEGFR1 and VEGFR2 are almost 
undetectable in normal testis, both receptors are overexpressed in tumor endothelial cells 
and in GCTs themselves [25, 26]. VEGF mRNA and protein is also significantly 
overexpressed in GCTs. VEGF expression correlates with the microvascular density 
within the tumors and allows for the identification of patients at risk for metastatic 
disease in some [27] though not all studies [28]. 
Platelet-derived growth factor (PDGFR) has been implicated in the development of the 
male gonad [29], and platelet-derived growth factor (PDGF) and PDGFR are important 
for the development of Leydig cells and myoid cells. Also, PDGFR has been detected in 
testicular GCT [30] during the initial stages of GCT development [31].  
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Here we present what is, to our knowledge, the first case reported in the literature of a 
patient with a metastatic GCT, refractory to HDT, who progressed after bevacizumab-
based chemotherapy, and in whom sunitinib showed clinical activity. 
Clinical Case 
A 24-year-old male patient was sent to our unit from another center. He was diagnosed in 2005 of an 
enlarging left testicular mass. In July 2005, he was operated with a left inguinal orchiectomy. The 
pathologic study revealed a mixed GCT with areas of seminoma, choriocarcimona and endodermal 
sinus tumor. Human chorionic gonadotropin (HCG) was 329 IU/ml (<5 mIU/ml), and alphafetoprotein 
(AFP) of 8,730 ng/ml (>10 ng/ml); lactate dehydrogenase (LDH) was normal. The extension study 
revealed multiple lung nodules compatible with metastatic extension, 2 liver metastases of 77 and 60 
mm and 2 retroperitoneal masses of 15 cm each. 
The patient received 4 cycles of BEP (bleomycin 30 mg i.v. day 1, 8, 15; etoposide 120 mg/m
2 day 1–
5; and cisplatin 20 mg/m
2 day 1–5) every 3 weeks, obtaining only a partial response. All the lung nodules 
disappeared, liver metastases did not show any change, and the retroperitoneal masses presented partial 
response. Subsequently, the patient was offered to continue chemotherapy with paclitaxel 250 mg/m
2 
followed by ifosfamide 1,500 mg/m
2 days 2–5, and cisplatin 25 mg/m
2 days 2–5, mesna 500 mg/m
2 4 h 
before and 8 h after each dose of ifosfamide (TIP). He completed 4 cycles, obtaining a complete clinical 
remission. HCG was 23 mIU/ml and AFP 20 ng/ml. At this time, a PET/CT was performed and did not 
reveal any hypercaptation area; thus, the patient was considered for follow-up. 
In January 2007, biochemical (HCG 2,142 mIU/ml) and radiological progression in the liver and 
retroperitoneal lymph nodes were documented. The patient initiated TIP chemotherapy for a total of 3 
cycles, with a complete clinical response, followed by an autologous bone marrow transplant (BMT). 
The conditionating treatment consisted of etoposide 750 mg/m
2 and carboplatin 700 mg/m
2 days –6 to 
–4; and on April 27
th, 2007, stem cells were infused at 4.43 × 106 CD34+/kg. A complete clinical and 
serological response was obtained and the patient was included in a follow-up program. 
In December 2007, an increase of HCG levels to 1,881 mIU/ml with a negative CT and PET was 
detected. The patient began chemotherapy with oxaliplatin 85 mg/m
2 day 1. After 3 cycles of 
chemotherapy, HCG level increased to 21,332 mIU/ml, and liver, lung and retroperitoneal metastases 
were observed. The patient then came to our center. 
After evaluating the case, we decided to consider chemotherapy with carboplatin AUC 5-docetaxel 
60 mg/m
2 and bevacizumab 10 mg/kg every 3 weeks, under compassionate use, based on the results 
obtained by the group of Voigt et al. [32]. After 3 cycles of chemotherapy, the CT scan revealed liver, 
lung and retroperitoneal progression, HCG was then 27,865 mIU/ml, thus the treatment was 
discontinued; a new compassionate use authorization for treatment with sunitinib was solicited and 
authorized. 
The patient began sunitinib 37,5 mg on a daily basis in June 2008. The initial level of HCG was 
37,258 mIU/ml. After 2 weeks of treatment, it had increased to 73,782 mIU/ml, and after 4 weeks, it had 
decreased to 36,153 mIU/ml; in week 6 it was 25,155 mIU/ml, which could be considered similar to the 
flare effect that sometimes happens with sunitinib in prostate cancer (fig. 1). The control at day 60 
reflected 22,365 mIU/ml and on the last disposable control on day 75, the level of HCG was at 19,805 
mIU/ml. A new CT scan was performed which showed, compared with the scan performed in May, an 
increase in size of the retroperitoneal lesions, but with an increase of necrosis, close to the response 
observed with gastrointestinal stromal tumors (fig. 2). After day 75, the patient came to the emergency 
room of our hospital and died with a massive retroperitoneal bleeding and hematuria after a motocross 
accident. 
Discussion 
The treatment of patients with GCT has evolved significantly over the past 30 years 
because cisplatin-based chemotherapy plus adjunctive surgery cures advanced metastatic 
tumors and the potential rescue of patients with BMT exists. For patients who progress 
after BMT, the only accepted treatment in this context is the combination of gemcitabine  
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and oxaliplatin [33], which may offer prolonged survival for some patients. Treatment of 
refractory patients is challenging and in many of them it harbors an evolution that marks 
the onset of inexorable terminal progression. The only exception to this rule are patients 
with elevated serum markers and a solitary site of metastases. Effective treatments are 
urgently needed for salvage treatment of patients whose disease progresses and becomes 
chemoresistant. A rationale exists for the use of sunitinib in these patients based on the 
genetic aberrations of tumors that involve VEGT, c-KIT and PDGFR, which are all 
inhibited by the drug. 
To our knowledge, this is the first reported case of a GCT treated with sunitinib. 
Because of the obtained result we can recommend its use and development in the 
treatment of refractory GCT. 
 
 
 
 
 
Fig. 1. Evolution of the HCG level. 
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Fig. 2. Upper panel: CT scan May 2008. Lower panel: CT scan July 2008. 
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